Lumipulse^® G ADxPLORER^® BD-Tau

Plasma BD-Tau has been identified as a superior biomarker of neurodegeneration compared with plasma total tau, as it exclusively reflects central nervous system (CNS)-derived Tau. BD-Tau is considered a promising biomarker for amyloid-related neurodegeneration¹, and has also shown potential for predicting clinical outcomes following acute ischemic stroke^2,3, traumatic brain injury⁴, as well as for prognostic assessment in Creutzfeldt-Jakob disease⁵. Notwithstanding these studies indicating its potential, its clinical value remains to be further established.

The Lumipulse® G ADxPLORER® BD-Tau assay was developed using a proprietary BD-Tau monoclonal antibody ADx219 (90498) in conjunction with an alkaline phosphatase-conjugated Fab fragment derived from the N-terminal recombinant ADx218 mAb (90563). The assay is calibrated using full-length recombinant Tau441.
 

References:

1. Gonzalez-Ortiz et al. Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer's disease. Nat Commun. 2024 Apr 4;15(1):2908.
2. Vlegels et al. Brain-derived Tau for Monitoring Brain Injury in Acute Ischemic Stroke. medRxiv [Preprint]. 2023 Nov 19:2023.11.18.23298728.
3. Stanne et al. Association of Plasma Brain-Derived Tau with Functional Outcome After Ischemic Stroke. Neurology. 2024 Feb 27;102(4):e209129. 
4. Gonzalez-Ortiz et al. Association of Serum Brain-Derived Tau with Clinical Outcome and Longitudinal Change in Patients With Severe Traumatic Brain Injury. JAMA Netw Open. 2023 Jul 3;6(7):e2321554.
5. Bentivenga et al. Clinical value of novel blood-based tau biomarkers in Creutzfeldt-Jakob disease. Alzheimers Dement. 2024 Dec 6. 
6. Vanbrabant et al. Novel plasma pTau205 and BD-tau prototype assays on LUMIPULSE® G1200. Alzheimer’s Dement. 2024;20(Suppl. 8):e095460.

Lumipulse is a registered trademark of Fujirebio Inc.
ADxPLORER is a registered trademark of Fujirebio Europe NV.